Fr. 135.00

Lower Extremity Arterial Disease

English · Hardback

Shipping usually within 6 to 7 weeks

Description

Read more

A comprehensive review the state-of-the-art in atherosclerosis of the arteries of the legs and feet. The authors discuss in detail the primary symptom-claudication-an intermittent pain in the leg or foot while walking, its predisposing factors, the current diagnostic methodologies, the impressive advances in the therapeutic armamentarium, and the need to screen for co-existing coronary artery disease. Additional chapters describe cutting-edge noninvasive angiography and vascular flow studies, specific drug therapy for claudication, regression of atherosclerosis therapy, gene therapy, and drug eluting stents for peripheral arterial disease. The authors also examine the epidemiology of LEAD, the effects of smoking and effective smoking cessation programs, its pathogenesis and its association with lipid abnormalities and hypertension, aggressive risk factor modification, and the need to measure the ankle brachial index of every patient over 45. Although associated with coronary heart disease and generalized arteriosclerosis in a large number of patients, lower extremity arterial disease (LEAD) is a disease process by itself that only one in four patients will survive more than 10 years. Approximately 10 million men and women in the United States suffer from LEAD. In Lower Extremity Arterial Disease, leaders in the fields of cardiovascular medicine, hypertension, vascular surgery, vascular radiology, and vascular physiology join forces to comprehensively review the state-of-the-art concerning atherosclerosis of the arteries of the legs and feet. The authors discuss in detail LEAD's primary symptom-claudication-an intermittent pain in the leg or foot while walking, its predisposing factors, the current diagnostic methodologies, the impressive advances in the therapeutic armamentarium, and the need to screen for co-existing coronary artery disease. Additional chapters describe cutting-edge noninvasive angiography and vascular flow studies, specific drug therapy for claudication, regression of atherosclerosis therapy, gene therapy, and drug-eluting stents for peripheral arterial disease. The authors also examine the epidemiology of LEAD, the effects of smoking and effective smoking cessation programs, its pathogenesis and its association with lipid abnormalities and hypertension, aggressive risk factor modification, and the need to measure the ankle-brachial index of every patient over 45.
Authoritative and up-to-date, Lower Extremity Arterial Disease offers family physicians, cardiologists, internists, radiologists, and cardiovascular surgeons a comprehensive analysis of all aspects of LEAD, ranging from diagnostic methodologies and pharmacotherapy to aggressive risk factor modification, transcatheter therapeutics, and gene therapy.

List of contents

Claudication.- Noninvasive Diagnostic Evaluation of Peripheral Arterial Disease.- Smoking and Smoking Cessation.- Peripheral Arterial Disease and Diabetes.- Hyperlipidemia in Peripheral Arterial Disease.- Hypertension and Peripheral Vascular Disease.- Physical Inactivity is a Risk Factor for Lower Extremity Arterial Disease and Coronary Heart Disease.- Pathogenesis of Atherosclerotic Vascular Disease.- Lower Extremity Arterial Disease Co-Existing With Coronary Artery Disease.- Medical Therapy of Claudication and Lower Extremity Arterial Disease.- Exercise Therapy for Lower Extremity Arterial Disease.- Endovascular Strategies for Management of Claudication and Lower Extremity Arterial Disease.- Severe Lower Extremity Arterial Disease.

Summary

A comprehensive review the state-of-the-art in atherosclerosis of the arteries of the legs and feet. The authors discuss in detail the primary symptom-claudication-an intermittent pain in the leg or foot while walking, its predisposing factors, the current diagnostic methodologies, the impressive advances in the therapeutic armamentarium, and the need to screen for co-existing coronary artery disease. Additional chapters describe cutting-edge noninvasive angiography and vascular flow studies, specific drug therapy for claudication, regression of atherosclerosis therapy, gene therapy, and drug eluting stents for peripheral arterial disease. The authors also examine the epidemiology of LEAD, the effects of smoking and effective smoking cessation programs, its pathogenesis and its association with lipid abnormalities and hypertension, aggressive risk factor modification, and the need to measure the ankle brachial index of every patient over 45.

Additional text

"...outstanding...provide(s) guidance for modern physicians on an ancient, but still poorly recognized, group of disorders." - Comprehensive Therapy

Report

"...outstanding...provide(s) guidance for modern physicians on an ancient, but still poorly recognized, group of disorders." - Comprehensive Therapy

Product details

Authors Dennis G. Caralis
Assisted by George L. Bakris (Editor), Dennis G. Caralis (Editor), Denni G Caralis (Editor), Dennis G Caralis (Editor), L Bakris (Editor), L Bakris (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Hardback
Released 06.01.2011
 
EAN 9781588295545
ISBN 978-1-58829-554-5
No. of pages 306
Weight 641 g
Illustrations XIII, 306 p.
Series Clinical Hypertension and Vascular Diseases
Clinical Hypertension and Vasc
Clinical Hypertension and Vascular Diseases
Clinical Hypertension and Vasc
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

Management, B, Medicine, Heart, diagnosis, Therapy, differential diagnosis, vascular surgery, Pain, hypertension, atherosclerosis, Gene Therapy, coronary artery disease, vascular disease, arteries

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.